318 related articles for article (PubMed ID: 10553698)
21. Mechanism of plasmid-mediated quinolone resistance.
Tran JH; Jacoby GA
Proc Natl Acad Sci U S A; 2002 Apr; 99(8):5638-42. PubMed ID: 11943863
[TBL] [Abstract][Full Text] [Related]
22. The RuvAB branch migration complex can displace topoisomerase IV.quinolone.DNA ternary complexes.
Shea ME; Hiasa H
J Biol Chem; 2003 Nov; 278(48):48485-90. PubMed ID: 13679378
[TBL] [Abstract][Full Text] [Related]
23. Comparison of inhibition of Escherichia coli topoisomerase IV by quinolones with DNA gyrase inhibition.
Hoshino K; Kitamura A; Morrissey I; Sato K; Kato J; Ikeda H
Antimicrob Agents Chemother; 1994 Nov; 38(11):2623-7. PubMed ID: 7872758
[TBL] [Abstract][Full Text] [Related]
24. Fluoroquinolones: action and resistance.
Drlica K; Malik M
Curr Top Med Chem; 2003; 3(3):249-82. PubMed ID: 12570763
[TBL] [Abstract][Full Text] [Related]
25. Topoisomerase Inhibitors: Fluoroquinolone Mechanisms of Action and Resistance.
Hooper DC; Jacoby GA
Cold Spring Harb Perspect Med; 2016 Sep; 6(9):. PubMed ID: 27449972
[TBL] [Abstract][Full Text] [Related]
26. Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage-enhancing antineoplastic drugs.
Elsea SH; Westergaard M; Burden DA; Lomenick JP; Osheroff N
Biochemistry; 1997 Mar; 36(10):2919-24. PubMed ID: 9062121
[TBL] [Abstract][Full Text] [Related]
27. Importance of the fourth alpha-helix within the CAP homology domain of type II topoisomerase for DNA cleavage site recognition and quinolone action.
Strumberg D; Nitiss JL; Dong J; Walker J; Nicklaus MC; Kohn KW; Heddle JG; Maxwell A; Seeber S; Pommier Y
Antimicrob Agents Chemother; 2002 Sep; 46(9):2735-46. PubMed ID: 12183223
[TBL] [Abstract][Full Text] [Related]
28. Mode of action of the quinolone antimicrobial agents: review of recent information.
Hooper DC; Wolfson JS
Rev Infect Dis; 1989; 11 Suppl 5():S902-11. PubMed ID: 2549608
[TBL] [Abstract][Full Text] [Related]
29. Distinct effects of the UvrD helicase on topoisomerase-quinolone-DNA ternary complexes.
Shea ME; Hiasa H
J Biol Chem; 2000 May; 275(19):14649-58. PubMed ID: 10799552
[TBL] [Abstract][Full Text] [Related]
30. Mechanism of fluoroquinolone action.
Drlica K
Curr Opin Microbiol; 1999 Oct; 2(5):504-8. PubMed ID: 10508721
[TBL] [Abstract][Full Text] [Related]
31. Interactions between fluoroquinolones, Mg2+, DNA and DNA gyrase, studied by phase partitioning in an aqueous two-phase system and by affinity chromatography.
Khac SB; Moreau NJ
J Chromatogr A; 1994 May; 668(1):241-7. PubMed ID: 7516247
[TBL] [Abstract][Full Text] [Related]
32. Type II topoisomerases as targets for quinolone antibacterials: turning Dr. Jekyll into Mr. Hyde.
Anderson VE; Osheroff N
Curr Pharm Des; 2001 Mar; 7(5):337-53. PubMed ID: 11254893
[TBL] [Abstract][Full Text] [Related]
33. Activity of quinolones against gram-positive cocci: mechanisms of drug action and bacterial resistance.
Schmitz FJ; Higgins PG; Mayer S; Fluit AC; Dalhoff A
Eur J Clin Microbiol Infect Dis; 2002 Sep; 21(9):647-59. PubMed ID: 12373497
[TBL] [Abstract][Full Text] [Related]
34. Bacillus anthracis GrlAV96A topoisomerase IV, a quinolone resistance mutation that does not affect the water-metal ion bridge.
Aldred KJ; Breland EJ; McPherson SA; Turnbough CL; Kerns RJ; Osheroff N
Antimicrob Agents Chemother; 2014 Dec; 58(12):7182-7. PubMed ID: 25246407
[TBL] [Abstract][Full Text] [Related]
35. Advances in DNA gyrase inhibitors.
Kim OK; Ohemeng K; Barrett JF
Expert Opin Investig Drugs; 2001 Feb; 10(2):199-212. PubMed ID: 11178337
[TBL] [Abstract][Full Text] [Related]
36. Interactions between DNA helicases and frozen topoisomerase IV-quinolone-DNA ternary complexes.
Shea ME; Hiasa H
J Biol Chem; 1999 Aug; 274(32):22747-54. PubMed ID: 10428858
[TBL] [Abstract][Full Text] [Related]
37. Antibacterial action of quinolones: from target to network.
Cheng G; Hao H; Dai M; Liu Z; Yuan Z
Eur J Med Chem; 2013 Aug; 66():555-62. PubMed ID: 23528390
[TBL] [Abstract][Full Text] [Related]
38. Relationship between mutations in the DNA gyrase and topoisomerase IV genes and nadifloxacin resistance in clinically isolated quinolone-resistant Staphylococcus aureus.
Oizumi N; Kawabata S; Hirao M; Watanabe K; Okuno S; Fujiwara T; Kikuchi M
J Infect Chemother; 2001 Sep; 7(3):191-4. PubMed ID: 11810583
[TBL] [Abstract][Full Text] [Related]
39. Quinolone action against human topoisomerase IIalpha: stimulation of enzyme-mediated double-stranded DNA cleavage.
Bromberg KD; Burgin AB; Osheroff N
Biochemistry; 2003 Apr; 42(12):3393-8. PubMed ID: 12653542
[TBL] [Abstract][Full Text] [Related]
40. Exploring DNA topoisomerases as targets of novel therapeutic agents in the treatment of infectious diseases.
Tse-Dinh YC
Infect Disord Drug Targets; 2007 Mar; 7(1):3-9. PubMed ID: 17346206
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
